Navigation Links
Onyx Pharmaceuticals Announces First Quarter 2008 Financial Results Teleconference and Webcast
Date:4/29/2008

EMERYVILLE, Calif., April 29 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will webcast a teleconference with management to discuss first quarter 2008 financial results and provide a general business overview on Tuesday, May 6, 2008, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Financial results for the first quarter ended March 31, 2008 will be released earlier that day.

Interested parties may access a live webcast of the presentation on our website at: http://www.onyx-pharm.com/wt/page/event_calendar or by dialing 630-691-2760 and using the passcode 21488196. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 21488196 approximately one hour after the teleconference concludes. The replay will be available through June 6, 2008.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated(TM). The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R), a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer, and other cancers. For more information about Onyx, visit the company's website at http://www.onyx-pharm.com.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Core Informatics Delivers Enterprise Core LIMS Installation to BioRelix Pharmaceuticals
2. Syndexa Pharmaceuticals Corporation and ChemDiv, Inc. Announce Discovery Collaboration
3. Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing
4. Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
5. Keryx Biopharmaceuticals Receives Nasdaq Notification
6. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
7. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition
9. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
10. New Fragment-based Drug Discovery Platform Announced Between IOTA Pharmaceuticals Ltd, Cambridge (UK), and Beactica AB, Uppsala (Sweden)
11. MacroChem Acquires Virium Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" ... Liver Congress ("ILC") 2017 of the European Association for the ... on the positive effects of PBI-4050 on reduction of ... metabolic syndrome. ... Dr. Lyne Gagnon, Vice-President of R&D Pre-clinical of Prometic "This ...
(Date:4/20/2017)... , April 20, 2017 Dutch philosopher Koert van ... ,Next Nature, at the University of Technology in Eindhoven - has written ... this letter, he calls on humanity to avoid becoming a slave and victim ... ... Dutch philosopher Koert van Mensvoort – founder of the ...
(Date:4/19/2017)... ... April 18, 2017 , ... A number of new instruments ... which is part of the Protein and Cell Analysis Education Webinar Series , ... this technology fits in current and future applications. , Many flow cytometers have ...
(Date:4/19/2017)... ... April 19, 2017 , ... ThermaGenix, the PCR Improvement Company, ... to several other early achievements at ThermaGenix, including the business formation and licensing ... ThermaGenix will use proceeds from the Series A-1 round to:, ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
(Date:3/30/2017)... 30, 2017 Trends, opportunities and forecast in ... by technology (fingerprint, AFIS, iris recognition, facial recognition, hand ... by end use industry (government and law enforcement, commercial ... banking, and others), and by region ( North ... Asia Pacific , and the Rest of ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
Breaking Biology News(10 mins):